Enquiry Now
Loading...
| A03345 | Pages: NA | Aug 2021 | 4235 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Hospital Acquired Urinary Tract Infection Market
Request Now !Hospital acquired urinary tract infections are caused by patients urethral catheters or invasive manipulation in the urogenital tract, which allows microbes to enter into the bladder and encourages proliferation by providing a sustainable environment. Hospital acquired UTIs are accountable for over 50% of infections. An array of tests can uncover type of infection and pathogen associated with the infection to efficiently treat the infected area.
Increase in prevalence of hospital acquired UTIs and technological advancement in testing devices drive the market. Moreover, favorable reimbursement scenario and focused disease management boost the market growth. However, strict regulatory policies and introduction of new testing devices into the market restrict the growth. Surge in preference over substitute products such as anti-infection catheters impedes the market growth.
The global hospital acquired urinary tract infection market is segmented on the basis of product, application, technology, disease, end user, and geography. On the basis of product, the market is divided into microbial testing instruments, reagents and consumables, infection prevention, and surveillance software. The microbial testing instruments are further divided into automated microbial identification systems, polymerase chain reaction (PCR) instruments, mass spectrometers, microarrays, polystainers, flow cytometers, and others. By application, the market is classified into disease testing, drug-resistance testing. On the basis of technology, the market is divided into phenotypic methods (phage-based assays, colorimetric methods, and nitrate reductase assay) and genotypic methods (DNA sequencing, solid-phase hybridization techniques, polymerase chain reaction techniques, microarrays). By diseases, the market is categorized into hospital acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal infections, urinary tract infections (UTI), and others. By end user, the market is segmented into hospitals and intensive care units (ICUs), ambulatory surgical and diagnostic centers, nursing homes and maternity centers, and others. By geography, it is analyzed across North America, Europe, Asia Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major market players such as Advanced Sterilization Products (Division Ethicon Us, LLC), Becton, Dickinson and Company, Steris Corporation, Getinge Group, Kimberly-Clark Corporation, Cantel Medical, Biomerieux SA, Belimed AG, 3M Company, Sterigenics International LLC., Synergy Health, and PLC are provided in this report.
Key Benefits
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities
CHAPTER 4 HOSPITAL ACQUIRED URINARY TRACT INFECTION MARKET, BY PRODUCT
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. MICROBIAL TESTING INSTRUMENTS
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Automated Microbial Identification Systems
4.2.5. Polymerase Chain Reaction (PCR) Instruments
4.2.6. Mass Spectrometers
4.2.7. Microarrays
4.2.8. Polystainers
4.2.9. Flow Cytometers
4.2.10. Others
4.3. REAGENTS AND CONSUMABLES
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. INFECTION PREVENTION AND SURVEILLANCE SOFTWARE
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
CHAPTER 5 HOSPITAL ACQUIRED URINARY TRACT INFECTION MARKET, BY APPLICATION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. DISEASE TESTING
5.2.1. Market size and forecast
5.3. DRUG-RESISTANCE TESTING
5.3.1. Market size and forecast
CHAPTER 6 HOSPITAL ACQUIRED URINARY TRACT INFECTION MARKET, BY TECHNOLOGY
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. PHENOTYPIC METHODS
6.2.1. Market size and forecast
6.2.2. Phage-based Assays
6.2.3. Colorimetric Methods
6.2.4. Nitrate Reductase Assay
6.3. GENOTYPIC METHODS
6.3.1. Market size and forecast
6.3.2. DNA Sequencing
6.3.3. Solid-phase Hybridization Techniques
6.3.4. Polymerase Chain Reaction Techniques
6.3.5. Microarrays
CHAPTER 7 HOSPITAL ACQUIRED URINARY TRACT INFECTION MARKET, BY DISEASE
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. HOSPITAL ACQUIRED PNEUMONIA
7.2.1. Market size and forecast
7.3. BLOODSTREAM INFECTIONS
7.3.1. Market size and forecast
7.4. SURGICAL SITE INFECTIONS
7.4.1. Market size and forecast
7.5. GASTROINTESTINAL INFECTIONS
7.5.1. Market size and forecast
7.6. URINARY TRACT INFECTIONS (UTI)
7.6.1. Market size and forecast
7.7. OTHERS
7.7.1. Market size and forecast
CHAPTER 8 HOSPITAL ACQUIRED URINARY TRACT INFECTION MARKET, BY END USER
8.1. OVERVIEW
8.1.1. Market size and forecast
8.2. HOSPITALS AND INTENSIVE CARE UNITS (ICUS)
8.2.1. Market size and forecast
8.3. AMBULATORY SURGICAL AND DIAGNOSTIC CENTERS
8.3.1. Market size and forecast
8.4. NURSING HOMES AND MATERNITY CENTERS
8.4.1. Market size and forecast
8.5. OTHERS
8.5.1. Market size and forecast
CHAPTER 9 HOSPITAL ACQUIRED URINARY TRACT INFECTION MARKET, BY GEOGRAPHY
9.1. OVERVIEW
9.2. NORTH AMERICA
9.2.1. Key market trends
9.2.2. Key growth factors and opportunities
9.2.3. Market size and forecast
9.2.3.1. U.S. market size and forecast
9.2.3.2. Canada market size and forecast
9.2.3.3. Mexico market size and forecast
9.3. EUROPE
9.3.1. Key market trends
9.3.2. Key growth factors and opportunities
9.3.3. Market size and forecast
9.3.3.1. Germany market size and forecast
9.3.3.2. France market size and forecast
9.3.3.3. UK market size and forecast
9.3.3.4. Italy market size and forecast
9.3.3.5. Spain market size and forecast
9.3.3.6. Rest of Europe market size and forecast
9.4. ASIA-PACIFIC
9.4.1. Key market trends
9.4.2. Key growth factors and opportunities
9.4.3. Market size and forecast
9.4.3.1. Japan market size and forecast
9.4.3.2. China market size and forecast
9.4.3.3. Australia market size and forecast
9.4.3.4. India market size and forecast
9.4.3.5. South Korea market size and forecast
9.4.3.6. Taiwan market size and forecast
9.4.3.7. Rest of Asia-Pacific market size and forecast
9.5. LAMEA
9.5.1. Key market trends
9.5.2. Key growth factors and opportunities
9.5.3. Market size and forecast
9.5.3.1. Brazil market size and forecast
9.5.3.2. Turkey market size and forecast
9.5.3.3. Saudi Arabia market size and forecast
9.5.3.4. South Africa market size and forecast
9.5.3.5. Rest of LAMEA market size and forecast
CHAPTER 10 COMPANY PROFILES
10.1. ADVANCED STERILIZATION PRODUCTS (DIVISION ETHICON US, LLC)
10.1.1. Operating business segments
10.1.2. Business performance
10.1.3. Key strategic moves and developments
10.2. BECTON, DICKINSON AND COMPANY
10.2.1. Operating business segments
10.2.2. Business performance
10.2.3. Key strategic moves and developments
10.3. STERIS CORPORATION
10.3.1. Operating business segments
10.3.2. Business performance
10.3.3. Key strategic moves and developments
10.4. GETINGE GROUP
10.4.1. Operating business segments
10.4.2. Business performance
10.4.3. Key strategic moves and developments
10.5. KIMBERLY-CLARK CORPORATION
10.5.1. Operating business segments
10.5.2. Business performance
10.5.3. Key strategic moves and developments
10.6. CANTEL MEDICAL, BIOMERIEUX SA
10.6.1. Operating business segments
10.6.2. Business performance
10.6.3. Key strategic moves and developments
10.7. BELIMED AG
10.7.1. Operating business segments
10.7.2. Business performance
10.7.3. Key strategic moves and developments
10.8. 3M COMPANY
10.8.1. Operating business segments
10.8.2. Business performance
10.8.3. Key strategic moves and developments
10.9. STERIGENICS INTERNATIONAL LLC
10.9.1. Operating business segments
10.9.2. Business performance
10.9.3. Key strategic moves and developments
10.10 SYNERGY HEALTH, AND PLC
10.10.1 Operating business segments
10.10.2 Business performance
10.10.3 Key strategic moves and developments
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
10%
Discount
10%
Discount
10%
Discount
10%
Discount
Enterprise
License/PDF
10%
Discount
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
